HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

AbstractPURPOSE:
Glioblastoma multiforme (GBM) remains highly incurable, with frequent recurrences after standard therapies of maximal surgical resection, radiation, and chemotherapy. To address the need for new treatments, we have undertaken a chimeric antigen receptor (CAR) "designer T cell" (dTc) immunotherapeutic strategy by exploiting interleukin (IL)13 receptor α-2 (IL13Rα2) as a GBM-selective target.
EXPERIMENTAL DESIGN:
We tested a second-generation IL13 "zetakine" CAR composed of a mutated IL13 extracellular domain linked to intracellular signaling elements of the CD28 costimulatory molecule and CD3ζ. The aim of the mutation (IL13.E13K.R109K) was to enhance selectivity of the CAR for recognition and killing of IL13Rα2(+) GBMs while sparing normal cells bearing the composite IL13Rα1/IL4Rα receptor.
RESULTS:
Our aim was partially realized with improved recognition of tumor and reduced but persisting activity against normal tissue IL13Rα1(+) cells by the IL13.E13K.R109K CAR. We show that these IL13 dTcs were efficient in killing IL13Rα2(+) glioma cell targets with abundant secretion of cytokines IL2 and IFNγ, and they displayed enhanced tumor-induced expansion versus control unmodified T cells in vitro. In an in vivo test with a human glioma xenograft model, single intracranial injections of IL13 dTc into tumor sites resulted in marked increases in animal survivals.
CONCLUSIONS:
These data raise the possibility of immune targeting of diffusely invasive GBM cells either via dTc infusion into resection cavities to prevent GBM recurrence or via direct stereotactic injection of dTcs to suppress inoperable or recurrent tumors. Systemic administration of these IL13 dTc could be complicated by reaction against normal tissues expressing IL13Ra1.
AuthorsSeogkyoung Kong, Sadhak Sengupta, Betty Tyler, Anthony J Bais, Qiangzhong Ma, Saryn Doucette, Jinyuan Zhou, Ayguen Sahin, Bob S Carter, Henry Brem, Richard P Junghans, Prakash Sampath
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 18 Issue 21 Pg. 5949-60 (Nov 01 2012) ISSN: 1557-3265 [Electronic] United States
PMID22966020 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright©2012 AACR.
Chemical References
  • CD28 Antigens
  • Interleukin-13
  • Interleukin-13 Receptor alpha2 Subunit
  • Receptors, Antigen, T-Cell
Topics
  • Animals
  • CD28 Antigens (genetics, immunology)
  • Cell Line, Tumor
  • Disease Models, Animal
  • Gene Order
  • Glioblastoma (immunology, mortality, therapy)
  • Humans
  • Immunotherapy, Adoptive (methods)
  • Interleukin-13 (genetics, immunology)
  • Interleukin-13 Receptor alpha2 Subunit (immunology, metabolism)
  • Mutation
  • Protein Multimerization
  • Receptors, Antigen, T-Cell (genetics, immunology, metabolism)
  • Signal Transduction
  • T-Lymphocytes (immunology, metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: